280 Utah Avenue
South San Francisco
About Annexon Biosciences
Annexon Biosciences is leading the development of therapeutic products that halt the progression of CMND. Our antibody pipeline is based on breakthrough research involving the classical complement pathway and the unique role of its initiating molecule, C1q, in triggering the loss of nerve connections and inducing inflammation in neurologic and ophthalmic disorders.
CEO: Douglas Love, Esq
Chief Scientific Officer: Ted Yednock, PhD
Chief Medical Officer: Mario Saltarelli, MD, PhD
7 articles with Annexon Biosciences
7/12/2019Biotech and pharma companies strengthen their leadership teams with new appointments.
Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders
Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer
With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.
Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.
Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor
BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.